Overview of DSIP: A Neuropeptide for Sleep Research

DSIP, also known as Emideltide, is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular formula of C35H48N10O15 and a molecular weight of 848.81 g/mol (PubChem CID: 3623358). First identified in 1974 by the Schoenenberger-Monnier group from rabbit cerebral venous blood during induced sleep, DSIP is an amphiphilic neuropeptide found in free and bound forms in the hypothalamus, pituitary, and peripheral tissues PMC, DSIP Review. Synthesized for research, it is supplied as a lyophilized powder (>98% purity, 5–10 mg vials) for reconstitution with bacteriostatic water, typically administered via subcutaneous or intravenous injection in preclinical studies

Investigated primarily for its sleep-promoting properties, DSIP is used in research to explore its effects on delta EEG activity, stress modulation, and hormone secretion, though its exact physiological role remains elusive due to the absence of an identified gene or receptor.

Its short half-life (~15 minutes in vitro) suggests complexation with carrier proteins in vivo to prevent degradation PMC, DSIP Review. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.

Mechanism of Action: Neuromodulation and Stress Regulation

DSIP influences sleep, neuroendocrine, and stress response pathways through mechanisms characterized in preclinical models, with limited human data PMC, DSIP Review.

• Sleep Regulation: DSIP induces spindle and delta EEG activity in rabbits, increasing SWS by 10–15% when infused intracerebroventricularly (7 nmol/kg), potentially via NMDA receptor modulation

• Neuroendocrine Modulation: DSIP alters serum levels of hormones, increasing adrenocorticotropic hormone (ACTH) and luteinizing hormone (LH) by 20–30% in rodent models, while suppressing somatostatin PMC, DSIP Neuroendocrinology.

• Stress Protection: DSIP reduces ROS by 10–20% and enhances oxidative phosphorylation in brain neurons, increasing hypoxia resistance in vitro PMC, DSIP Neuroprotection.

• Anti-Inflammatory Effects: It decreases pro-inflammatory cytokines (e.g., TNF-α) by 15–20% in stress models, potentially mitigating excitotoxicity PMC, DSIP Neuroprotection.

• Pharmacokinetics: In rodents, DSIP (100 µg/kg) achieves peak plasma concentrations within 5–10 minutes, with rapid degradation unless bound to carrier proteins PMC, DSIP Review.

Preclinical studies in rats showed DSIP (7 nmol/kg ICV) increased SWS by 10–15% in specific analogues, though native DSIP had inconsistent effects PMC, DSIP Analogues. Limited human trials (25 nmol/kg IV) reported a 59% increase in sleep duration in healthy subjects, with no significant side effects. Its research applications are confined to controlled settings.

Research Applications of DSIP: Insights from Preclinical and Limited Clinical Studies

DSIP’s neuromodulatory properties make it a valuable compound for investigating sleep, stress, and neuroendocrine regulation. The following applications are strictly for research purposes in controlled environments, supported by peer-reviewed findings:

Sleep and Circadian Rhythm Research

DSIP is studied for its potential to modulate sleep architecture:

• Intraventricular infusion (7 nmol/kg) in rabbits increased delta EEG activity by 10–15%, promoting SWS

• In human trials, single IV doses (25 nmol/kg) extended sleep duration by 59% in healthy subjects, with effects lasting up to 6 hours.

• Research explores DSIP’s role in circadian rhythm regulation, with plasma concentrations correlating with sleep initiation in mammals PMC, DSIP Neuroendocrinology.

Stress and Neuroprotection Studies

DSIP’s stress-protective effects are investigated in neurological models:

• A 20% reduction in ROS and excitotoxicity in neuronal cultures, enhancing hypoxia resistance PMC, DSIP Neuroprotection.

• Decreased seizure duration by 30% in metaphit-induced epilepsy models in rats, suggesting anticonvulsant potential PMC, DSIP Review.

• Potential applications in studying stroke recovery, with DSIP (1 mg/kg) improving motor function by 25% in rat focal stroke models PMC, DSIP Stroke.

Neuroendocrine Regulation Research

DSIP’s effects on hormone secretion are a key research focus:

• A 20–30% increase in ACTH and LH levels in rodent pituitary cultures, with no effect on CRH-stimulated cortisol release in humans PMC, DSIP Neuroendocrinology.

• Modulation of melatonin synthesis by 15% in aged rat pineal glands, supporting circadian studies PMC, DSIP Review.

• Research into DSIP’s role in hypothalamic-pituitary-adrenal (HPA) axis regulation, though mechanisms remain unclear

Anti-Aging and Cellular Longevity Research

DSIP’s antioxidant and anti-apoptotic effects are studied in aging models:

• A 2.6-fold reduction in spontaneous tumor incidence in mice treated lifelong with DSIP (0.1 µg/day), suggesting anticarcinogenic properties PMC, DSIP Review.

• A 24.1% increase in maximum lifespan in mice, with 22.6% fewer chromosome aberrations in bone marrow cells PMC, DSIP Aging.

• Potential to delay senescence by reducing p53 expression by 15–20% in cell cultures PMC, DSIP Neuroprotection.

Neurological Research Potential

Emerging data suggest DSIP’s role in neurological studies:

• A 10–15% reduction in oxidative stress in neuronal cultures, potentially protecting against neurodegeneration PMC, DSIP Stroke.

• No direct cognitive effects confirmed, with further research needed to validate neurological applications

These applications are confined to research settings, with no approved therapeutic use in humans.

Research Populations and Study Designs

DSIP’s research applications target specific investigational populations and study designs:

• Preclinical Researchers: Scientists studying sleep architecture, neuroprotection, or neuroendocrine regulation use DSIP in cell cultures and rodent models PMC, DSIP Review.

• Sleep and Chronobiology Investigators: Researchers examining SWS or circadian rhythms employ DSIP to explore delta EEG activity

• Neurology and Aging Scientists: Those investigating stroke, epilepsy, or cellular senescence use DSIP to study stress-protective mechanisms PMC, DSIP Stroke.

Typical study designs involve in vitro neuronal or pituitary cell cultures treated with 0.1–10 µg/mL DSIP or in vivo studies in rodents (7–100 µg/kg/day) for 1–4 weeks, measuring EEG activity, hormone levels, or oxidative stress markers. Limited human studies used IV doses (25 nmol/kg) over 1–4 days, assessing sleep metrics. All applications are investigational.

Research Limitations and Risks

Several limitations and considerations apply to DSIP research:

• Limited Human Data: Few clinical trials exist, with most effects derived from preclinical studies. Human trials show variable efficacy, particularly for sleep

• Regulatory Status: DSIP is not approved by the FDA or any regulatory body for human use and is designated for research purposes only PMC, DSIP Review.

• Side Effect Profile: Preclinical studies report no significant adverse effects at 7–100 µg/kg/day. Human trials note mild injection site reactions or headaches in <5% of subjects, with no serious adverse events

• Dosing Variability: Research doses (0.1–10 µg/mL in vitro, 7–100 µg/kg/day in vivo) lack standardization, requiring precise protocols PMC, DSIP Analogues.

• Theoretical Risks: DSIP’s proliferative effects (e.g., telomerase activation) could theoretically amplify unintended cellular responses, though no evidence supports this

Conclusion: A Versatile Tool for Sleep and Neuroendocrine Research

DSIP, a synthetic nonapeptide, offers significant potential as a research tool for studying sleep regulation, stress protection, and neuroendocrine modulation. Preclinical studies demonstrate a 10–15% increase in SWS, 20–30% enhanced hormone secretion, 30% reduced neuronal damage, and 24.1% extended lifespan in mice, providing insights into sleep, aging, and neuroprotection. For researchers investigating chronobiology, neurology, or longevity, DSIP is a precise instrument for controlled studies. However, its lack of human data, investigational status, and regulatory restrictions limit its use to laboratory research.

Key Citations

• DSIP comprehensive review

• DSIP sleep and insomnia research

• DSIP neuroendocrinology

• DSIP neuroprotection and stroke

• DSIP ageing and longevity

• DSIP analogues and sleep effects

• DSIP unresolved questions

Legal Disclaimer

The information provided in this article is for research purposes only. Delta Sleep-Inducing Peptide (DSIP) is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of DSIP in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving DSIP.

Additional information

Weight1 lbsDimensions1 × 1 × 1 in

COA

Overview of DSIP: A Neuropeptide for Sleep Research

DSIP, also known as Emideltide, is a nine-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular formula of C35H48N10O15 and a molecular weight of 848.81 g/mol (PubChem CID: 3623358). First identified in 1974 by the Schoenenberger-Monnier group from rabbit cerebral venous blood during induced sleep, DSIP is an amphiphilic neuropeptide found in free and bound forms in the hypothalamus, pituitary, and peripheral tissues PMC, DSIP Review. Synthesized for research, it is supplied as a lyophilized powder (>98% purity, 5–10 mg vials) for reconstitution with bacteriostatic water, typically administered via subcutaneous or intravenous injection in preclinical studies

Investigated primarily for its sleep-promoting properties, DSIP is used in research to explore its effects on delta EEG activity, stress modulation, and hormone secretion, though its exact physiological role remains elusive due to the absence of an identified gene or receptor.

Its short half-life (~15 minutes in vitro) suggests complexation with carrier proteins in vivo to prevent degradation PMC, DSIP Review. The following sections detail its mechanisms and research applications, emphasizing its role as a research-only compound.